CRIS Current Research Information System

GAMBINERI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.269
AS - Asia 6.430
EU - Europa 4.932
SA - Sud America 556
AF - Africa 382
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 5
Totale 19.594
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.168
SG - Singapore 1.763
CN - Cina 1.570
VN - Vietnam 1.537
IT - Italia 1.150
GB - Regno Unito 999
DE - Germania 609
HK - Hong Kong 528
SE - Svezia 465
IN - India 419
BR - Brasile 412
FR - Francia 346
RU - Federazione Russa 309
IE - Irlanda 189
UA - Ucraina 189
KR - Corea 141
ZA - Sudafrica 121
NL - Olanda 113
FI - Finlandia 107
JP - Giappone 106
TG - Togo 83
CH - Svizzera 82
CI - Costa d'Avorio 80
EE - Estonia 66
AR - Argentina 60
BG - Bulgaria 60
AT - Austria 51
CA - Canada 44
ID - Indonesia 44
PH - Filippine 43
IQ - Iraq 39
BE - Belgio 38
BD - Bangladesh 37
MX - Messico 31
PL - Polonia 27
SC - Seychelles 27
TR - Turchia 26
NG - Nigeria 24
JO - Giordania 23
TH - Thailandia 23
EC - Ecuador 22
ES - Italia 21
PK - Pakistan 20
TW - Taiwan 20
AU - Australia 17
GR - Grecia 16
AL - Albania 14
CL - Cile 14
IR - Iran 14
LB - Libano 13
PE - Perù 12
PY - Paraguay 12
HR - Croazia 11
RO - Romania 11
UZ - Uzbekistan 11
MA - Marocco 10
SA - Arabia Saudita 10
VE - Venezuela 10
DK - Danimarca 9
MY - Malesia 9
EG - Egitto 8
LT - Lituania 8
CO - Colombia 7
IL - Israele 7
PT - Portogallo 7
ET - Etiopia 6
HN - Honduras 6
NO - Norvegia 6
CZ - Repubblica Ceca 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
AE - Emirati Arabi Uniti 4
EU - Europa 4
KZ - Kazakistan 4
NP - Nepal 4
RS - Serbia 4
TN - Tunisia 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
GH - Ghana 3
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
OM - Oman 3
UY - Uruguay 3
CR - Costa Rica 2
GA - Gabon 2
GT - Guatemala 2
KW - Kuwait 2
NI - Nicaragua 2
PA - Panama 2
SN - Senegal 2
SV - El Salvador 2
ZW - Zimbabwe 2
AO - Angola 1
BF - Burkina Faso 1
BW - Botswana 1
Totale 19.573
Salva come PNG Salva come JPEG
Città #
Singapore 1.158
Southend 835
Ashburn 757
Fairfield 740
Hong Kong 490
Chandler 406
San Jose 391
Woodbridge 368
Bologna 352
Houston 334
Seattle 333
Wilmington 318
Ho Chi Minh City 315
Santa Clara 302
Hanoi 293
Hefei 254
Princeton 231
Dong Ket 225
Ann Arbor 217
Cambridge 211
Beijing 198
Dublin 189
Boardman 155
Los Angeles 143
Lauterbourg 134
Seoul 122
Jacksonville 117
Council Bluffs 116
Westminster 98
Nanjing 97
Milan 91
Hyderabad 89
Tokyo 88
New York 84
Lomé 83
Padova 83
Abidjan 80
Helsinki 77
Berlin 75
Buffalo 66
Bern 59
Sofia 58
Haiphong 56
Saint Petersburg 54
Guangzhou 50
São Paulo 49
Dallas 46
Redondo Beach 45
Da Nang 44
Jinan 44
San Diego 44
Shenyang 43
The Dalles 43
Frankfurt am Main 42
Munich 39
Redwood City 39
Changsha 35
Hebei 35
Redmond 35
Bremen 34
Vienna 34
Turin 31
Mülheim 29
Rome 29
Bengaluru 28
Shanghai 26
Tianjin 26
Amsterdam 25
Johannesburg 25
Nanchang 25
Norwalk 25
Brussels 24
Nuremberg 24
Orem 23
Zhengzhou 23
Abeokuta 22
Dearborn 22
Des Moines 22
Falls Church 22
Jakarta 22
Baghdad 21
Hải Dương 21
Amman 20
Can Tho 20
Olalla 19
Turku 19
Warsaw 19
Wuhan 19
London 18
Chicago 17
Florence 17
Phoenix 17
Boydton 15
Chennai 15
Jiaxing 15
Rio de Janeiro 15
Ninh Bình 14
San Francisco 14
Thái Nguyên 14
Brasília 13
Totale 12.458
Salva come PNG Salva come JPEG
Nome #
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial 438
Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome 314
Defining hyperandrogenism in women with polycystic ovary syndrome: A challenging perspective 286
Behavioral, socio-environmental, educational and demographic correlates of excess body weight in Italian adolescents and young adults 261
Insulin sensitizers in polycystic ovary syndrome 243
Altered adipocyte differentiation and unbalanced autophagy in type 2 Familial Partial Lipodystrophy: an in vitro and in vivo study of adipose tissue browning 232
Androgen Profiling by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) in Healthy Normal-Weight Ovulatory and Anovulatory Late Adolescent and Young Women 223
Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone 223
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women 221
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism 221
17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. 218
New insights on diabetes in Turner syndrome: results from an observational study in adulthood 215
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome 214
Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography - tandem mass spectrometry 211
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. 210
Obituary: Renato Pasquali (1946-2019) 207
The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk 205
In memoriam: Renato Pasquali (1946-2019) 200
Prevalence and Incidence of Atrial Fibrillation in a Large Cohort of Adrenal Incidentalomas: A Long-Term Study 196
A comprehensive approach in diagnosing the polycystic ovary syndrome 195
Sex hormones, obesity and type 2 diabetes: is there a link? 193
A new interaction to come: Ghrelin and steroid hormones 192
Anti-müllerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? 184
Impact of age, body weight and metabolic risk factors on steroid reference intervals in men 184
Efficacy of very low-calorie ketogenic diet with the Pronokal® method in obese women with polycystic ovary syndrome: a 16-week randomized controlled trial 183
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. 182
New insights into the comorbid conditions of Turner syndrome: results from a long-term monocentric cohort study 182
Short-term modification of sex hormones is associated with changes in ghrelin circulating levels in healthy normal-weight men. 180
Psychological aspects of hyperandrogenic states in late adolescent and young women. 180
SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial 179
Salivary cortisol and cortisone responses to short-term psychological stress challenge in late adolescent and young women with different hyperandrogenic states 179
Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction 176
The empowerment of translational research: lessons from laminopathies. 175
Clinical assessment of allostatic overload in adolescent and young women with hyperandrogenic states 173
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. 172
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. 168
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. 167
Androgens and Severe Insulin Resistance States: Basic and Clinical Aspects 167
Ketogenic nutritional therapy (KeNuT)-a multi-step dietary model with meal replacements for the management of obesity and its related metabolic disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-diet therapies in endocrinology and metabolism 163
Improving the diagnosis of 11β-hydroxylase deficiency using home-made MLPA probes: identification of a novel chimeric CYP11B2/CYP11B1 gene in a Sicilian patient 163
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. 162
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. 161
Evolution of cardiovascular risk factors and the risk for cardiovascular events in a Caucasian population with polycystic ovary syndrom 159
Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls 159
Prominent role of low HDL-cholesterol in explaining the high prevalence of the metabolic syndrome in polycystic ovary syndrome. 159
Liraglutide and Renal Outcomes in Type 2 Diabetes. 157
Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. 156
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. 156
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin 155
Hirsutism and virilization 155
The PCOS Phenotype in Unselected Populations (P-PUP) study: Ethnic variation in population-based normative cut-offs for defining hirsutism 154
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study. 153
Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. 153
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours 152
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution 148
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome. 147
Metabolic effects of obesity on reproduction. 147
Revisiting hyper- and hypo-androgenism by tandem mass spectrometry. 147
Sindrome dell'ovaio policistico e diabete di tipo 2 146
An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. 146
Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. 145
Molecular and phenotypical characterization of 10 families with 11ß-hydroxylase deficiency 144
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors 144
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. 143
Is it possible to achieve an acceptable disease control by dietary therapy alone in Berardinelli Seip type 1? Experience from a case report 142
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 142
Ghrelin and reproductive disorders. 142
High serum concentration of total inhibin in polycystic ovary syndrome 141
Biomediators in polycystic ovary syndrome and cardiovascular risk 141
Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. 139
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. 138
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS? 137
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS 136
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. 136
Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects 135
Liraglutide and cardiovascular outcomes in type 2 diabetes 134
Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia 134
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome 133
Quality of diet, screened by the Mediterranean diet quality index and the evaluation of the content of advanced glycation endproducts, in a population of high school students from Emilia Romagna 132
Steroid reference intervals in women: influence of menopause, age and metabolism 132
The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE) 131
Prevalence of Hyperandrogenic States in Late Adolescent and Young Women: Epidemiological Survey on Italian High-School Students 130
Targeting insulin sensitivity in the treatment of polycystic ovary syndrome 130
Insulin-sensitizing agents in polycystic ovary syndrome. 127
Sex-dependent role of glucocorticoids and androgens in the pathophysiology of human obesity 124
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors 124
The role of low-grade inflammation in the polycystic ovary syndrome. 123
Mechanisms and treatment of obesity in polycystic ovary syndrome 122
Cytokine Profile in Striated Muscle Laminopathies: New Promising Biomarkers for Disease Prediction 122
Role of changes in dietary habits in polycystic ovary syndrome. 119
Case Report: An Atypical Form of Familial Partial Lipodystrophy Type 2 Due to Mutation in the Rod Domain of Lamin A/C 118
Type 2 diabetes and the polycystic ovary syndrome. 117
Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology 116
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. 116
Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions 116
Validation of an LC–MS/MS salivary assay for glucocorticoid status assessment: Evaluation of the diurnal fluctuation of cortisol and cortisone and of their association within and between serum and saliva 115
European survey of diagnosis and management of the polycystic ovary syndrome: Results of the ESE PCOS Special Interest Group's Questionnaire 114
European lipodystrophy registry: Background and structure 114
Parallel diurnal fluctuation of testosterone, androstenedione, dehydroepiandrosterone and 17OHprogesterone as assessed in serum and saliva: validation of a novel liquid chromatography-tandem mass spectrometry method for salivary steroid profiling 114
Insulin-sensitizing agents in women with polycystic ovary syndrome. 112
Totale 16.521
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.382
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021568 0 0 0 0 0 0 0 0 0 90 74 404
2021/20221.999 161 57 119 132 193 94 71 165 73 134 478 322
2022/20232.170 233 295 93 305 148 131 69 114 350 165 158 109
2023/2024728 77 116 54 48 54 114 53 48 16 77 48 23
2024/20252.882 108 445 272 185 411 148 212 101 69 214 159 558
2025/20266.922 576 689 661 618 746 421 1.003 286 1.415 507 0 0
Totale 19.940